Merhavia Holdings: The Cardiaxens watch has been approved by the Ministry of Health – Capital Market



Merhavia Holdings

Merhavia Holdings






Page Quote News Graphs Company Profile Recommendations

More articles on the subject:

It is reported that the holding company (5.67%) CardiacSense has received the approval of the Medical Equipment Division of the Ministry of Health for registration in the medical equipment register of the first model of the medical watch developed by CardiacSense for the purpose of heart rate monitoring and atrial fibrillation diagnosis. The permit will be valid until the end of January 2021.

The Cardiacens medical watch is designed to measure heart rate and heart rate on a single beat basis and to detect the presence of atrial fibrillation lasting at least 5 minutes by using ECG and PGG.





The medical equipment register is the certificate book of medical accessories and devices approved by the Medical Equipment Division of the Ministry of Health. The medical watches that Cardiaxens is developing include the ability to detect arrhythmias, including atrial fibrillation, which is one of the main causes of stroke.

In June, Merhavia reported an additional investment of $ 250,000 in CardiacSense, at a company value of approximately $ 46 million, as part of a round of funding totaling approximately $ 6 million. Merhavia will have the right to purchase additional shares totaling up to $ 150,000 at a discount of approximately 20% in relation to the next raising value or a value of $ 64 million (for the full article).

Merhavia previously worked in the field of income-producing real estate and wind energy. During 2015, the company’s board of directors approved investments in the field of biomed. Since then, the company has entered into several investments in biomed companies with an emphasis on advanced distance medicine solutions. ), As part of which it has invested in CDx in the field of cancer diagnostics. In addition, Merhavia invests in 5 other companies including Crediaxence, Trainpain in the field of chronic pain treatment, EFA in the field of blood count tests, Juventas in the field of genetic therapy and Violi La innovative technology for cannabis consumption in precise dosage.

Comments on the article(0):

Your response has been received and will be published subject to system policies.

For a new response

Your response was not sent due to a communication problem, please try again.

Return to comment


Please enter your comment!
Please enter your name here